Intranasal SB-705498 in Allergic Rhinitis (AR) Patients

GlaxoSmithKline70 enrolled

Overview

This study is designed to look at the affect of SB-705498 on allergic rhinitis symptoms induced by an allergen chamber challenge.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Rhinitis

Interventions

SB-705498DRUG

12mg intranasal

FPDRUG

200ug intranasal

placeboDRUG

placebo intranasal

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosis of AR, as determined by the presence of rhinitis symptoms that last for several months per year, for more than 1 year and are not attributed to allergy, infections or nasal abnormalities. 2. TNSS score of \>=4 following screening allergen challenge chamber. 3. Positive skin prick test for seasonal pollen 4. Positive RAST for seasonal pollen 5. Healthy as determined by responsible physician with the exception of mild asthma and AR 6. Male or female between 18 and 65 years of age inclusive. 7. A female subject is eligible to participate if she is of: * Non-childbearing potential defined as pre-menopausal females with a \\documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 MlU/ml and estradiol \< 40 pg/ml (\<147 pmol/L) is confirmatory\]. * Child-bearing potential and agrees to use one of the contraception methods listed as instructed. Female subjects must agree to use contraception until 84 days post-last treatment administration. 8. Male subjects with female partners of child-bearing potential must agree to use one contraception as instructed. This must be followed from the time of the first dose of study medication until 84 days post-last treatment administration. 9. Body weight ≥ 50 kg (males) and ≥45kg (females) and BMI within the range 19 - 29.9 kg/m2 (inclusive). 10. Screening pre-challenge FEV1 greater than or equal to 80% and baselines FEV1/FVC greater than or equal to 70% of predicted value. 11. Capable of giving written informed consent. 12. Average QTcB, \< 450 msec; or QTc \< 480 msec in subjects with Bundle Branch Block. 13. AST and ALT \< 2xULN; alkaline phosphatase and bilirubin less than or equal to 1.5xULN Exclusion Criteria: 1. Nasal abnormalities likely to affect the outcome of the study, 2. History of frequent nosebleeds. 3. Respiratory disease other than mild asthma 4. A positive pre-study Hepatitis B or Hepatitis C result within 3 months of screening 5. Current or chronic history of liver disease, or known hepatic or biliary abnormalities 6. Positive pre-study drug/alcohol/smoking screen. 7. A positive test for HIV antibody. 8. History of regular alcohol consumption within 6 months of the study defined as: • An average weekly intake of \>14 drinks for males or \>7 drinks for females. 9. The subject has participated in a clinical trial and has received an investigational product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product prior to D1. 10. Exposure to more than four new chemical entities within 12 months prior to D1. 11. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days prior to the first dose of study medication. 12. History of sensitivity to any of the study medications, or components 13. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. 14. Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing. 15. Lactating females. 16. Subject is mentally or legally incapacitated. 17. Urine cotinine levels indicative of smoking

Locations (1)

GSK Investigational Site

Vienna, Austria

Outcomes

Primary Outcomes

Mean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8

Nasal symptoms (nasal congestion, rhinorrhoea, itching and sneezing) were scored on a scale from 0 to 3 where 0= absent symptoms, 3 = severe symptoms. TNSS was calculated as the sum of the response for all 4 individual nasal symptom scores. TNSS ranged from 0 to 12, where 0=absent symptoms, 3=severe symptoms. Higher the score, more severe the symptoms. Weighted mean (WM) of TNSS and its individual components (nasal congestion, rhinorrhoea, itching and sneezing) are presented on Day 8. Weighted mean was calculated over the time interval 0 to 4 hours after start of allergen chamber challenge by calculating the area under the curve of TNSS/component from time of the first observation to time of the last observation (AUC \[tf-t1 hours\]) using the trapezoidal rule, and then dividing by the actual relevant time interval (tf-t1) required by participant to complete the chamber challenge assessments. A Bayesian analysis was conducted to derive the posterior probability for TNSS.

Time frame: Day 8 of each treatment period

Secondary Outcomes

Mean TNSS and Its Individual Components From Day 4 to Day 8

Time frame: pre-evening (pm) dose on Days 4, 5, 6, 7 and pre-challenge [1 hour (hr)] on Day 8 of each treatment period

Total Nasal Airflow on Day 8 Measured Using Active Anterior Rhinomanometry (AAR)

Total Nasal Airflow is calculated as the sum of the left nostril and the right nostril airflow values. AAR is a very sensitive method of assessing clinical parameters of nasal obstruction (nasal flow, nasal resistance and nasal flow increase). A participant was instructed to breathe through one nostril while a sensor in the other nostril measured the difference in pre-nasal and choanal pressure. The system was connected to a computer. Nasal flow and nasal resistance were observed at pressure levels of 75, 150 and 300 Pascal. The defined measuring range for the flow was +-1000 milliliter per second (mL/s). Weighted means for total nasal airflow Resistance was calculated by dividing the area under the curve between 1 and 4 hours (via the linear trapezoidal method) by the total duration that the participant took to complete the chamber challenge assessments.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Following Repeat Doses of SB-705498 or or SB-705498 Matching Placebo

The RQLQ composed of 28 items covering 7 domains of health. Each question is scored on a scale of 0 to 6 (where, 0 = not troubled and 6 = extremely troubled). 7 domains were: Activities (3 items):1, 2, 3;Sleep (3 items): 4, 5, 6; Non-nose/eye symptoms (7 items): 7, 8, 9, 10, 11, 12, 13; Practical Problems (3 items): 14, 15, 16; Nasal Symptoms (4 items): 17, 18, 19, 20; Eye Symptoms (4 items): 21, 22, 23, 24; Emotional (4 items): 25, 26, 27, 28 consisted of total 28 items. Domain activity score = total post-baseline score for individualized activity items answered on both visits divided by total Baseline score for individualized activity items answered on both visits multiplied by the Baseline score for item(s) missing post-baseline. The global RQLQ score was calculated by averaging all 28 item scores, which ranges from 0 to 6 (where, 0 = not troubled and 6 = extremely troubled). Higher scores indicate worsening of symptoms.

Time frame: Day 8

Area Under Concentration-time Curve (AUC) for SB-705498 on Day 8

Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. AUC0-t was calculated by the linear trapezoidal method. AUC0-infinity was calculated as the sum of the AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, where first-order elimination or terminal rate constant was calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. Values were reported as Least Squares Geometric Means with respective % CV.

Time frame: Period 1: Day 1 (post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h), Period 2 and 3: Day 1 (Pre-dose 0.0 h, post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h)

Maximum Observed Concentration (Cmax) for SB-705498 on Day 8

Plasma samples for pharmacokinetic analysis were drawn at indicated time points of each treatment period. Cmax was defined as maximal measured plasma concentration over the time span specified. Values were reported as least squares geometric means with respective geometric coefficient of variation (% CV).

Number of Participants With Vital Signs of Potential Clinical Importance (PCI)

Vital signs assessment included heart rate, blood pressure, and temperature. Criteria for vital sign values meeting potential clinical concern included: systolic blood pressure (SBP) \<85 and \>160 millimeters of mercury (mm Hg), diastolic blood pressure (DBP) \< 45 and \> 100 mm Hg, temperature \<36 and \>37.5 Degree Celsius and heart Rate \<40 and \>110 beats per minute. Only parameters with PCI values are reported.

Time frame: Up to Week 16

Change From Baseline in ECG Values: Heart Rate

Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated heart rate and measured PQ, QRS, QT, and QTc intervals. Baseline was assessment on Day 1. Change from Baseline was the values at specified time points subtracted by the Baseline value.

Time frame: Baseline and Day 8 of each treatment period

Change From Baseline in ECG Values: PR Interval, QRS Duration, QT Interval, QTcB, QTcF

Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated heart rate and measured PQ, QRS, QT, QTc corrected by Bazett's formula (QTcB) and QTc corrected by Fridericia's formula (QTcF). Baseline was assessment on Day 1. Change from Baseline was the values at specified time points subtracted by the Baseline value.

Time frame: Baseline and Day 8 of each treatment period

Number of Participants With Hematology Parameters of PCI

The PCC range for hematology parameters included white blood cell count, low: 0.67, high 1.82, neutrophil count, low: 0.83, Hemoglobin, male- high 1.03, female- high 1.13, hematocrit, male- high 1.02, female- high 1.17, Platelet Count, low: 0.67, high: 1.57, lymphocytes, low 0.81. Only parameters with PCI values are reported.

Time frame: Up to Week 16

Number of Participants With Clinical Biochemistry Parameters of PCI

The PCC range for clinical chemistry parameters included albumin, low: 0.86, millimole per liter (mmol)/L, calcium, low: 0.91, high: 1.06, glucose. Low: 0.71, high: 1.41, Potassium, low: 0.86, high: 1.10, Sodium, low: 0.96, high: 1.03, Total CO2, Low: 0.86, high: 1.14, Creatinine, in male, Low: \<75 micromole per liter (μmol/L), high: \>110 μmol/L, female, Low: \<65 μmol/L, high: \>95, Blood Urea Nitrogen (BUN), high: \>1.5xULN mmol/L, Uric Acid, in male, Low: \< 180 μmol/L, high: \> 480 μmol/L, female, Low: \< 120 μmol/L, high: \> 420. Only parameters with PCI values are reported.

Time frame: Up to Week 16